CD274 and neoplasm: Studies on NIO use in MCC (e.g., neoadjuvant cemiplimab, ClinicalTrials.gov ID NCT04975152; and neoadjuvant nivolumab and relatlimab, ClinicalTrials.gov ID NCT06151236) together with predictive markers such as MCPyV status, PD-L1, or tumor mutational status to determine MCC immunotherapy efficacy are ongoing.15,16 Also of future interest is an optimal regimen for NIO and the prognostic and practice-changing implications for patients who may have a complete pathologic response to NIO.